Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Sweden
/
Pharmaceuticals & Biotech
Create a narrative
Swedish Orphan Biovitrum Community
OM:SOBI Community
1
Narratives
written by author
0
Comments
on narratives written by author
11
Fair Values set
on narratives written by author
Create a narrative
Swedish Orphan Biovitrum
Popular
Undervalued
Overvalued
Community Investing Ideas
Swedish Orphan Biovitrum
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
New Product Launches And Global Expansion Will Strengthen Future Prospects
Key Takeaways Strategic product launches and international expansion plans are expected to drive revenue growth and improve net margins through increased scale and distribution reach. Broadened portfolio through new indications and maintaining financial discipline could bolster earnings growth and improve EBITDA margins medium-term.
View narrative
SEK 358.17
FV
22.9% undervalued
intrinsic discount
10.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
1 day ago
author updated this narrative
Your Valuation for
SOBI
SOBI
Swedish Orphan Biovitrum
Your Fair Value
SEK
Current Price
SEK 276.00
19.1% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-268m
40b
2015
2018
2021
2024
2025
2027
2030
Revenue SEK 39.6b
Earnings SEK 5.9b
Advanced
Set Fair Value